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OBJECTIVE — To describe pregnancy outcome in type 1 diabetic women with normoalbu-
minuria, microalbuminuria, or diabetic nephropathy after implementation of an intensiﬁed
antihypertensive therapeutic strategy.
RESEARCH DESIGN AND METHODS — Prospective study of 117 pregnant women
with type 1 diabetes. Antihypertensive therapy, mainly methyldopa, was given to obtain blood
pressure 135/85 mmHg and urinary albumin excretion 300 mg/24 h. Blood pressure and
A1C were recorded during pregnancy. The pregnancy outcome was compared with recently
published studies of pregnant women with microalbuminuria or diabetic nephropathy.
RESULTS — Antihypertensive therapy was given in 14 of 100 women with normoalbumin-
uria, 5 of 10 women with microalbuminuria, and all 7 women with diabetic nephropathy. Mean
systolic blood pressure during pregnancy was 120 mmHg (range 101–147), 122 mmHg (116–
135), and 135 mmHg (111–145) in women with normoalbuminuria, microalbuminuria, and
diabetic nephropathy, respectively (P  0.0095). No differences in mean diastolic blood pres-
sure or A1C were detected between the groups. No women with microalbuminuria developed
preeclampsia. The frequency of preterm delivery was 20% in women with normoalbuminuria
andmicroalbuminuriaincontrastto71%inwomenwithdiabeticnephropathy(P0.01)where
the median gestational age was 258 days (220–260). Compared with previous studies using less
stringent antihypertensive therapeutic strategy and less strict metabolic control, gestational age
was longer and birth weight was larger in our study.
CONCLUSIONS — With intensiﬁed antihypertensive therapy and strict metabolic control,
comparable pregnancy outcome was seen in type 1 diabetic women with microalbuminuria and
normoalbuminuria. Although less severe than in previous studies, diabetic nephropathy was
associated with more adverse pregnancy outcome.
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T
ype 1 diabetic women with mi-
croalbuminuria or diabetic ne-
phropathy are at particular risk of
poor pregnancy outcome (1–6). Diabetic
nephropathyisassociatedwithahighrisk
of gestational hypertension, preeclamp-
sia, and preterm delivery (1–4,6). Like-
wise, preeclampsia and preterm delivery
occur more frequently in type 1 diabetic
women with microalbuminuria (3,5).
Outside pregnancy, the importance
of antihypertensive therapy with ACE in-
hibition to reduce the risk of renal com-
plications is well documented in both
type 1 diabetic patients with microalbu-
minuria (7) and diabetic nephropathy
(8).Topreventdevelopmentofhyperten-
sion and proteinuria, ACE inhibition has
been documented to be effective even in
normotensive diabetic women with mi-
croalbuminuria (7). However, ACE inhi-
bition in early pregnancy has been
associated with congenital malformations
(9),whileuselateinpregnancymaycause
fetal renal failure (10). ACE inhibition
therefore should be discontinued before
conception or as soon as pregnancy is
conﬁrmed (9). In diabetic women with
microalbuminuria or diabetic nephropa-
thy, the effect of antihypertensive therapy
in relation to development and progres-
sionofhypertensionandproteinuriadur-
ing pregnancy seems promising when
using antihypertensive drugs considered
safe during pregnancy. However, this is
only sparsely investigated (1,3,5).
A retrospective study suggested that
early intervention with antihypertensive
therapy reduces the risk of preterm deliv-
ery in type 1 diabetic women with dia-
betic nephropathy (1).
Previously, we found an association
between early onset of antihypertensive
therapy in pregnant type 1 diabetic
women with microalbuminuria and a re-
duced prevalence of preterm delivery,
probably due to a reduced prevalence of
preeclampsia (5). Methyldopa was ﬁrst-
choice therapy based on reports of stable
utero-placentalbloodﬂow,fetalhemody-
namics (11,12), and long-term follow-up
(13).Giventhattheprevalenceofpreterm
delivery and preeclampsia was still high
(5), we speculated that pregnant type 1
diabetic women with microalbuminuria
or diabetic nephropathy would beneﬁt
from further intensiﬁed antihypertensive
therapy in early pregnancy. Therefore, in
2004, we intensiﬁed our treatment strat-
egy in early pregnancy in type 1 diabetic
women with microalbuminuria or dia-
betic nephropathy.
In this study, we describe the preg-
nancy outcome in type 1 diabetic women
according to their degree of albuminuria
after the implementation of an intensiﬁed
antihypertensive therapeutic strategy.
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METHODS— During the study pe-
riod 1 September 2004 to 31 August
2006, we conducted a prospective study
consecutivelyincludingallpregnanciesin
Danish-speaking Caucasian women with
pregestational type 1 diabetes (n  121)
referred before 14 completed gestational
weeks to the Center for Pregnant Women
with Diabetes, Rigshospitalet, which of-
fers a joint service involving only a few
experienced obstetricians and endocri-
nologists.Allwomenwerereferredfroma
well-deﬁned geographical area covering
2millioninhabitantsineasternDenmark.
Women with a single fetus living beyond
22 completed weeks were included in the
present analysis.
Two women with Addison’s disease
and inﬂammatory bowel disease, respec-
tively, were excluded to avoid the poten-
tial bias of competing disease. If a woman
hadmorethanonepregnancyinthestudy
period (n  2), only the ﬁrst pregnancy
was included. A total of 117 women were
included in the study and followed until
delivery.
Based on the mean of two measure-
mentsof24-hurinaryalbuminexcretions
(UAEs) at inclusion, the women were
classiﬁed as having normoalbuminuria
(UAE 30 mg/24 h), microalbuminuria
(30–299 mg/24 h), or diabetic nephrop-
athy (UAE 300 mg/24 h) accordingly
(3). In women with diabetic nephropa-
thy, UAE was also recorded at 14, 21, 27,
and 33 weeks. In the remaining women,
further analysis of UAE was performed if
proteinuria (1) was present in the ab-
sence of nitrites and leukocytes on a uri-
nary dipstick (Uristix, Bayer Diagnostics,
Bridgend, U.K.), which was checked rou-
tinely at each clinical visit. UAE was
analyzed by an enzyme-linked immu-
nosorbentassay(14).Inafewcases,when
24-h urine samples were not available, al-
bumin-to-creatinine ratio in a random
urine sample was performed. We previ-
ously reported high concordance be-
tween UAE and albumin-to-creatinine
ratio with a sensitivity of 94% and speci-
ﬁcity of 100% between the two methods
(15).
Blood pressure was measured with a
digital blood pressure monitor (A&D In-
struments, Abingdon, Oxon, U.K.) in a
sitting position after 5–10 min of rest.
Preeclampsia in women with normoalbu-
minuria or microalbuminuria was de-
ﬁned as blood pressure 140/90 mmHg
accompanied by proteinuria (1)o na
sterile urinary dipstick or 300 mg/24 h
(proteinuria of 300 mg/24 h approxi-
mates UAE of 190 mg/24 h) later than 20
weeks. In women with diabetic nephrop-
athy,thediagnosiswasbasedonthesame
ﬁndings accompanied by a sudden in-
crease of 15% in systolic or diastolic
blood pressure (3).
Antihypertensive therapy was initi-
ated during pregnancy if blood pressure
was 135/85 mmHg and/or UAE was
300 mg/24 h. When ACE inhibitors
were withdrawn during prepregnancy
planning or in the ﬁrst weeks of preg-
nancy, antihypertensive therapy was ini-
tiated unless UAE was normal or very low
in the microalbuminuric range, in which
case the women were observed without
antihypertensive therapy (5). Treatment
goals were blood pressure 135/85
mmHg and UAE 300 mg/24 h.
Methyldopa (5,11–13) was ﬁrst-
choice therapy in most cases and, when
indicated, labetalol and/or nifedipine (5)
were added. If given before pregnancy,
furosemide was continued during preg-
nancy to reduce the risk of rebound ﬂuid
retention with increased blood pressure
and UAE when discontinuing the drug
(16).
The majority of women were treated
with a basal-bolus insulin regimen. All
women registered their self-monitored
plasma glucose (SMPG) readings in dia-
betes diaries, which were evaluated at
eachclinicalvisit.RoutineSMPGwasrec-
ommended at least seven times daily to
obtain preprandial SMPG of 4.0–6.0
mmol/l, 90-min postprandial SMPG of
4.0–8.0 mmol/l, and prebedtime SMPG
of 6.0–8.0 mmol/l (17).
Allwomenvisitedourand/ortheirlo-
cal diabetes center at 1- or 2-week inter-
vals for diabetes control and blood
pressure monitoring. Folic acid supple-
mentation during the ﬁrst 12 weeks of
pregnancy was recommended. Struc-
tured preconceptional care was not
offered systematically.
At median 8 (range 5–13), 14 (12–
16),21(20–23),27(25–29),and33(31–
35) weeks, weight, A1C, serum
creatinine, insulin dose, and blood pres-
sure were recorded, as was the last re-
corded value of A1C and blood pressure
at 36 weeks. Median SMPG was calcu-
lated as previously described (17). A1C
was assayed at our center by a latex im-
munoagglutination inhibition method on
the same analyzer (DCA 2000, Bayer, En-
gland). Normal A1C range outside preg-
nancy was 4.7–6.3%, in early pregnancy
4.5–5.7%, and in late pregnancy 4.4–
5.6% (18). Serum creatinine was assayed
on a routine basis.
Diabetic retinopathy was diagnosed
with retinal photos at inclusion and at 28
weeks. Obstetrical ultrasound scanning
wasperformedonaroutinebasisatinclu-
sion; at 14, 21, 27, and 33 weeks; and
when indicated.
Gestational age was estimated based
on early ultrasound scanning. Labor was
routinely induced after 37–40 completed
weeks based on an individual evaluation
including duration of diabetes, presence
of diabetic complications, previous ob-
stetrichistory,andfetalsizeaimingatget-
ting as close as possible to full term.
Pretermdeliverycompriseddeliverybe-
fore 37 completed weeks and included
spontaneous delivery and delivery
based on medical indications, mainly
preeclampsia, fetal distress, and large-
for-gestational-age infants. Small-for-
gestational-age was deﬁned as 10th
centile and large-for-gestational-age
was deﬁned as 90th centile for gesta-
tional age and sex for a Danish standard
population(19).Perinatalmortalitywas
deﬁned as fetal death after 22 weeks
or neonatal death the ﬁrst week after
delivery.
Selective serotonin reuptake inhibi-
tors were given in four women. Thyroid
dysfunction was treated with levothyrox-
inein16andwiththiamazolein2,result-
ing in normal thyroid function in all 18
women during pregnancy.
From the midwifery consultation at
Rigshospitalet, 25 healthy pregnant
women matched for parity and age and
with uncomplicated pregnancies were re-
cruited in the ﬁrst part of pregnancy.
Blood pressure was recorded at median
14 (range 10–19), 28 (20–29), and 34
(32–38) weeks, and pregnancy outcome
was collected from patients’ records.
Mean systolic and diastolic blood pres-
sureswerecalculatedforvaluesat8,14,21,
27, and 33 weeks for diabetic women and
forvaluesat14,28,and34weeksinhealthy
pregnant women. The research protocol
was approved by the regional committees
for ethics and science and by the Danish
Data Protection Agency.
Statistical analysis
Dataaregivenasmedian(range)orn(%).
Categorical variables were compared by

2 or Fisher’s exact test, as appropriate.
Continuous variables were analyzed by
one-way ANOVA after logarithmic trans-
formation or by nonparametric tests
when appropriate.
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peated measurements of continuous data
were analyzed by a variance component
modelwiththecontinuousvariableasthe
dependent variable, “week” and “group”
(normoalbuminuria, microalbuminuria,
or diabetic nephropathy) as discrete co-
variates, and random woman effect as a
measure of each woman’s level during
pregnancy.
Differenceswereconsideredtobesta-
tistically signiﬁcant with a two-sided P
value 0.05. All statistical analyses were
performedusingSASversion9.1(SASIn-
stitute, Cary, NC).
RESULTS— At inclusion in early preg-
nancy, 100 (85%) diabetic women had
normoalbuminuria, 10 (9%) microalbu-
minuria, and 7 (6%) diabetic nephropathy.
Median gestational age at the ﬁrst visit was
61 days (range 37–94) with no difference
between the groups (P  0.30).
During pregnancy, mean systolic
blood pressure was 120 mmHg (101–
147), 122 mmHg (116–135), and 135
mmHg (111–145) in women with nor-
moalbuminuria, microalbuminuria,
and diabetic nephropathy, respectively
(P  0.0095). Corresponding mean di-
astolic blood pressure was 72 mmHg
(62–86), 75 mmHg (65–87), and 74
mmHg (71–86) (P  0.26). In women
with normoalbuminuria and mi-
croalbuminuria, no differences in mean
systolic blood pressure (P  0.42) or
mean diastolic blood pressure (P 
0.61) were detected. Mean systolic
blood pressure was higher in women
with diabetic nephropathy compared
withtheremainingwomen(P  0.016).
At inclusion, no differences in systolic
(P  0.09) or diastolic (P  0.20) blood
pressure were detected between women
with diabetic nephropathy and the re-
maining women (Figures A1a and A1b
are available in an online appendix at
http://dx.doi.org/10.2337/dc08-1526).
During pregnancy, mean systolic
blood pressure and mean diastolic blood
pressure were higher in 86 normoalbu-
minuric women not receiving antihyper-
tensive therapy during pregnancy
compared with healthy pregnant women
(120 mmHg [101–138] vs. 117 mmHg
[102–128], P  0.038; and 72 mmHg
[62–82] vs. 70 mmHg [56–78], P 
0.023).
The median UAE among women
with diabetic nephropathy was main-
tained well below 2,000 mg/24 h
throughout pregnancy (online appen-
dix Figure A1c). However, in late preg-
nancy, UAE exceeded 2,000 mg/24 h in
three women with diabetic nephropa-
thy who delivered preterm, mainly due
to preeclampsia (n  2).
In women with normoalbuminuria,
six (6%) were treated with antihyperten-
sive therapy before and during the entire
pregnancy, whereas eight (8%) initiated
antihypertensive therapy at median 30
weeks (range 14–36). Four (40%)
women with microalbuminuria were on
antihypertensive drugs before pregnancy,
whereas one microalbuminuric woman
initiated treatment at 19 weeks. All
women with diabetic nephropathy re-
ceived antihypertensive therapy during
pregnancy, of which four (57%) were on
treatment before pregnancy, whereas
treatment was initiated at the ﬁrst or sec-
ond visit in the remaining three women
(Table 1).
Table 1—Clinical data in 117 women with type 1 diabetes according to urinary albumin excretion at inclusion in early pregnancy and in 25
healthy pregnant women
Normoalbuminuria Microalbuminuria Diabetic nephropathy
Healthy pregnant
women
n 100 10 7 25
Age (years) 30.5 (21–42) 31 (21–34) 30 (23–39) 31 (26–43)
Duration of diabetes (years) 16 (1–36) 14 (1–31) 20 (5–32) —
UAE rate at inclusion (mg/24 h) 7 (3–29) 91 (30–198) 690 (450–3,290) —
Serum creatinine at inclusion (mol/l) 51 (33–75) 51 (41–69) 57 (42–95) —
A1C at inclusion (%) 6.7 (4.9–10.8) 6.9 (5.8–10.5) 6.5 (5.7–7.8) —
BMI before pregnancy (kg/m
2) 24.2 (17.3–43.8) 25.6 (21.0–34.4) 25.0 (20.4–32.4) —
Weight gain during pregnancy (kg) 15.2 (5.6–34.4) 14.5 (9.3–26.4) 14.6 (9.3–22.8) —
ACE inhibitor therapy before pregnancy 12 (12) 4 (40) 5 (71)* —
Number of women on antihypertensive
therapy at some point in pregnancy
14 (14) 5 (50) 7 (100) —
Number of antihypertensive agents used
during pregnancy in women treated
with these drugs
1.5 (1–3) 1 (1–2) 2 (1–4) —
Diabetic retinopathy 63 (63) 5 (50) 7 (100)† —
Preeclampsia 7 (7) 0 3 (43)‡ 0
Gestational age (days) 265 (155–276) 264 (252–272) 258 (220–260) 282 (264–296)
Preterm delivery 34 gestational weeks 1 (1) 0 1 (14) 0
Preterm delivery 37 gestational weeks 20 (20) 2 (20) 5 (71)* 0
Birth weight (g) 3,540 (445–5,620) 3,430 (2,510–4,484) 2,765 (2,040–3,730)‡ 3,510 (2,840–4,970)
Small-for-gestational-age infants (10th
centile)
1 (1) 0 2 (29)* 2 (8)
Large-for-gestational-age infants (90th
centile)
50 (50) 5 (50) 1 (14) 2 (8)
Perinatal mortality (n) 2 (2) 0 0 0
Data are n (%) or medians (range). *P  0.01, †P  0.0503, ‡P  0.02 between women with diabetic nephropathy and the remaining diabetic women.
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thy had increased serum creatinine (89
and 95 mol/l at inclusion, increasing to
101 and 125 mol/l at 33 weeks, normal
nonpregnant range 50–88 mol/l). Glo-
merular ﬁltration rate measured before
pregnancywas48and56ml/min,respec-
tively.Twoyearsandonepregnancylater,
glomerular ﬁltration rate was 45 and 51
ml/min, respectively. Serum creatinine
was within the normal range at inclusion
in all other women (Table 1) and re-
mained stable throughout pregnancy in
the remaining women with diabetic ne-
phropathy (62 mol/l [44–74] at 33
weeks, n  4) and in all women with mi-
croalbuminuria(52mol/l[39–85]at33
weeks).
Throughout pregnancy, A1C de-
creased (online appendix Figure A1d),
medianSMPGlevelsremainedstable(on-
line appendix Figure A1e), and insulin
dose increased (data not shown) with no
differences between the three groups.
Early preterm delivery before 34
completedweeksoccurredinonewoman
with diabetic nephropathy due to fetal
distress and in one woman with nor-
moalbuminuriawhoexperiencedrupture
of the membranes at 22 completed weeks
and delivered an infant that died within 5
min. An unexplained death occurred a
few hours after delivery in a term-born
infant of a woman with normoalbumin-
uria. No major congenital malformations
or stillbirths were recorded.
None of the women with microalbu-
minuria developed preeclampsia, and the
frequency of preterm delivery among
womenwithmicroalbuminuriawasequal
tothatinwomenwithnormoalbuminuria
(Table 1). In women with diabetic ne-
phropathy,threedevelopedpreeclampsia
resulting in preterm delivery at 35–36
weeks. Median gestational age was 258
days in offspring of women with diabetic
nephropathy. A higher frequency of pre-
eclampsia(P0.013)andpretermdeliv-
ery (P  0.007) was thus seen in women
with diabetic nephropathy compared
with the remaining women. Spontaneous
preterm labor occurred in three nor-
moalbuminuricwomen,i.e.,in11%ofall
preterm deliveries, whereas the remain-
ing preterm deliveries were based on ob-
stetric indications. Birth weight did not
differbetweeninfantsofwomenwithnor-
moalbuminuria and microalbuminuria
butwaslowerinwomenwithdiabeticne-
phropathy (P  0.017). Furthermore in-
fants of women with diabetic nephropathy
more often were small-for-gestational-age
(P  0.01).
A comparison of blood pressure con-
trol and pregnancy outcome with recent
studies (published within 10 years) in
women with microalbuminuria or dia-
betic nephropathy is shown in Table 2
and Table 3.
CONCLUSIONS — In this prospec-
tive study of 117 pregnant women with
type1diabetes,weshowedthatafterearly
intervention with antihypertensive ther-
apy comparable pregnancy outcome was
seen in type 1 diabetic women with mi-
croalbuminuria and normoalbuminuria,
respectively. Although less severe than in
previous studies, diabetic nephropathy
was associated with more adverse preg-
nancy outcomes.
The importance of antihypertensive
and renoprotective therapy in nonpreg-
nant type 1 diabetic patients is well estab-
lished (7,8). However, only a few recent
studies have focused on the effect of anti-
hypertensive therapy in pregnant type 1
diabetic women with microalbuminuria
(3,5) or diabetic nephropathy (1–3), with
eachstudyhavinglimitationsduetosmall
numbers of patients (3,5), retrospective
design (1,2), or missing information
about the antihypertensive therapy strat-
egy (2). Until larger randomized prospec-
tivetrialsmightbecomeavailable,thereis
Table 2—Comparison of pregnancy outcomes in studies of pregnant type 1 diabetic women with microalbuminuria covering the same
geographical area in Eastern Denmark
Ekbom et al.,
2001 (3)
Nielsen et al.,
2006 (5) Current study
Antihypertensive therapy strategy Preeclampsia
Diastolic BP 95 mmHg
BP 140/90 mmHg
UAE 2 g/24 h
ACE inhibitor before
pregnancy
BP 135/85 mmHg
UAE 300 mg/24 h
ACE inhibitor before
pregnancy
n 26 20 10
Duration of diabetes (years) 19  51 8  81 5  10
A1C at inclusion (%) 8.1  0.9 6.8  0.5 7.3  1.5
Antihypertensive therapy (week of onset) 29 (20–34) 13 (before to 34) Before (before to 14)
Patients on antihypertensive therapy during pregnancy (n) 9 (35) 10 (50) 5 (50)
ACE inhibitor before pregnancy (n) 5 (19) 9 (45) 4 (40)
Systolic BP at inclusion (mmHg) 121  13 121  14 117  14
Diastolic BP at inclusion (mmHg) 71  87 3  87 4  8
UAE (mg/24 h) 69 (16–278) 74 (30–287) 91 (30–198)
Preeclampsia (n) 11 (42) 4 (20) 0
Gestational age at delivery (days) 250 (182–270) 259 (244–271) 264 (252–272)
Preterm delivery before 34 weeks (n) 6 (23) 0 0
Preterm delivery before 37 weeks (n) 16 (62) 8 (40) 2 (20)
Birth weight (g) 3,124  767 3,279  663 3,471  670
Perinatal mortality (n) 1 (4) 0 0
Major congenital malformations (n) 1 (4) 0 0
Data are means  SD, medians (range), or n (%). BP, blood pressure. Duration of diabetes, A1C, BP, and birth weight in the current study are given as means  SD
to compare results with previous studies from our center (3,5).
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experience regarding indications for and
timing of antihypertensive therapy in
pregnant women with type 1 diabetes.
Thisstudysupportspreviousﬁndings
that intensiﬁed antihypertensive therapy
may reduce adverse pregnancy outcomes
in women with microalbuminuria (5) or
diabetic nephropathy (1,2). In the major-
ity of women with microalbuminuria or
diabetic nephropathy receiving antihy-
pertensivetherapyduringpregnancy,this
therapy was indeed initiated before preg-
nancy. However, three women with dia-
betic nephropathy did not receive
antihypertensive therapy before preg-
nancy, mainly because of poor compli-
ance. Blood pressure levels within target
range(135/85mmHg)wereobtainedin
the vast majority of women in all three
categories of UAE. The antihypertensive
therapy was well tolerated, and side ef-
fectswerenotnoted.Compliancewasnot
measured but was estimated to be good.
At our center, we have previously
evaluated the effect of antihypertensive
therapy in pregnant diabetic women with
microalbuminuria (3,5) and gradually
over the years intensiﬁed our antihyper-
tensive therapy strategy accordingly. The
present article describes pregnancy out-
comes of three cohorts of unselected type
1diabeticwomenwithmicroalbuminuria
from the same geographical area treated
by the same doctors (P.D., E.R.M.) ac-
cording to three different antihyperten-
sive therapy strategies. Microalbuminuria
was previously associated with a high
prevalence of preeclampsia and preterm
delivery (3,5). With gradually intensiﬁed
antihypertensive strategies, a decrease in
rates of preeclampsia and preterm deliv-
ery was seen (Table 2), resulting in preg-
nancy outcome comparable with that of
women with normoalbuminuria.
With the current antihypertensive
strategy, infants of women with diabetic
nephropathy were delivered at a notably
later gestational age compared with pre-
vious studies from our (3) and other
(1,2,4,6) centers, which used less inten-
sive antihypertensive strategies. In the
currentstudy,birthweightofinfantsborn
to women with diabetic nephropathy was
substantially higher than in previous
studies (1–3) and only two infants were
small-for-gestational-age. Nonetheless,
the majority of infants of women with di-
abetic nephropathy were born preterm
and were smaller compared with the re-
maining infants of diabetic mothers. No
neonatal deaths were recorded in women
with diabetic nephropathy, but because
of the low number of women studied, no
ﬁrm conclusion regarding infrequent
pregnancy outcomes can be drawn.
Women with diabetic nephropathy
weremorepronetodeveloppreeclampsia
in agreement with previous studies (1–
4,6,20). Hod et al. (21) reported that in
eight highly selected type 1 diabetic
women with diabetic nephropathy, ACE
inhibitionbeforepregnancyofferedapro-
longed protective renal effect throughout
pregnancy with favorable pregnancy out-
come. In the current study, however, two
of three women with diabetic nephropa-
thydevelopingsuperimposedpreeclamp-
sia received ACE inhibition before
pregnancy.
Serum creatinine was used as an in-
dex of renal function as in the study of
Dunne et al. (2), who found increasing
serum creatinine during pregnancy in
women with diabetic nephropathy. In
contrast, we found stable serum creati-
nine in the women with microalbumin-
uria or diabetic nephropathy if serum
creatinine was within normal range in
early pregnancy in accordance with
Table3—Comparisonofpregnancyoutcomesinstudiesoftype1diabeticwomenwithdiabeticnephropathyreceivingantihypertensivetherapy
during pregnancy
Dunne et al.,
1999 (2)
Ekbom et al.,
2001 (3)
Carr et al.,
2006 (1)§ Current study
Antihypertensive therapy strategy Not speciﬁed Preeclampsia
diastolic BP 95 mmHg
Mean arterial BP
100 mmHg
BP 135/85 mmHg
UAE 300 mg/24 h
ACE inhibitor
prepregnancy
n 21 11 43 7
Duration of diabetes (years) 19.5 (12–30) 16 (5) 16.9 20 (5–32)
A1C at inclusion (%) 9.7 (6.7–16.7)‡ 8.8 (1.3) 8.1 6.6 (0.6)
Antihypertensive therapy before
pregnancy (n)
— 6 (55%) 18 (42%)* 5 (71%)
Patients on antihypertensive therapy
during pregnancy (n)
— — 39 (90.7%) 7 (100%)
Systolic BP at inclusion (mmHg) — 129 (11) 138 131 (19)
Diastolic BP at inclusion (mmHg) — 77 (8) 82 76 (9)
UAE at inclusion (mg/24 h) — 1,120 (466–5,528) 3,170 690 (450–3,290)
Preeclampsia (n) — 7 (64%) 15 (35%) 3 (43%)
Duration of pregnancy (days) 243 (203–266) — 238 258 (220–260)
Preterm delivery before 37 weeks (n) 12 (57.2%) 10 (91%) 16 (38.1%)† 5 (71%)
Birth weight (g) 2,429 (985–4,140) 2,235 (1,038) 2,200 2,730 (601)
Small-for-gestational-age infants
(10th centile)
— 5 (45%) — 2 (29%)
Perinatal mortality (n) 2 (10%) 0 4 (9%) 0
Major congenital malformations (n) 1 (5%) 1 (9%) — 0
Data are means (SD), median (range), or n (%). A1C and birth weight in the current study are given as means (SD) to compare with previous results from our center
(3). BP, blood pressure. *Patients using antihypertensive therapy at ﬁrst visit. †Preterm delivery before 32 weeks. §Modiﬁed from Carr et al. (1) to constitute one
group. ‡HbA1 or A1C (2).
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bers were too small for solid conclu-
sions. Women with diabetic
nephropathy were followed with fre-
quent determinations of UAE, whereas
in women with normoalbuminuria or
microalbuminuria, further analysis of
UAE was only performed systematically
whendipstickanalysiswas1during
pregnancy.Eveninthetwowomenwith
elevated serum creatinine during preg-
nancy, the annual change in glomerular
ﬁltration rate of 1.5–3 ml/min was not
different from what could be expected
in the most optimally treated women
with diabetic nephropathy (22).
Antihypertensive therapy with up to
four drugs was indicated in the women
with diabetic nephropathy. Nonetheless,
their systolic blood pressure was slightly
higher compared with the remaining
pregnant diabetic women. This may re-
ﬂect long-term hemodynamic alterations
and necessitate an even more intensive
antihypertensive therapy strategy before
andduringpregnancy(1).Bloodpressure
levels were within target range in the vast
majority of women with microalbumin-
uria. Furthermore, in all women with
microalbuminuria and in the majority
of women with diabetic nephropathy,
median UAE was maintained below
2,000 mg/24 h, the limit for nephrotic
proteinuria.
Even in normoalbuminuric diabetic
women not receiving antihypertensive
therapy during pregnancy, blood pres-
sure was higher compared with the
healthy pregnant women as previously
described (23). This may be associated
with increased activity of the renin-
angiotensin system in type 1 diabetes,
which has previously been demon-
strated in pregnant (L.R.N., U. Ped-
ersen-Bjergaard, B. Thorsteinsson, F.
Boomsma, P.D., E.R.M., unpublished
data) and nonpregnant (24) patients
with type 1 diabetes.
When compared with previous
studies at our center (3,5), improved
glycemic control was obtained in early
pregnancy, which may in part explain
the lack of congenital malformations.
Notably,nodifferencesinA1Cwerede-
tected between women with nor-
moalbuminuria, microalbuminuria, or
diabetic nephropathy during preg-
nancy. A combined effect of improved
glycemic control and early intensive an-
tihypertensiveinterventionmayexplain
the improved pregnancy outcome ob-
tained in the majority of women with
microalbuminuria and diabetic ne-
phropathy in the current study.
Tosummarize,earlyantihypertensive
therapy and strict metabolic control in
pregnantwomenwithtype1diabetesand
microalbuminuria or diabetic nephropa-
thy was associated with improved preg-
nancy outcome compared with recent
reports from our (3,5) and other (1,2)
centers.
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